

FY2009 FIRST-HALF RESULTS

(April 1, 2009 - September 30, 2009)

Supplementary Information

November 11th, 2009

<Contact>

Miraca Holdings Inc.

IR Public Relations Group

Phone: 03-5909-3337 Fax: 03-5909-3336

URL: <http://www.miraca-holdings.co.jp/>

Disclaimer regarding forward-looking statement:


The performance forecast provided in this document is prepared by the management based on currently available information and various hypotheses and ideas including significant risks or uncertainties. Please be aware that the actual performance may turn out to be different from the forecast as a result of various contributing factors.

Factors affecting the performance include, among others, aggravation of the economic situation, fluctuation of the exchange rate, change of regulatory, statutory, and administrative requirements, delayed launch of new products, pressures from the product strategies of competitive companies, and decline of the sales potential of existing products.

Consolidated Financial Highlights

(Millions of yen)

	FY2007		FY2008		FY2009		
	1H	Full-year	1H	Full-year	1H	YoY Variance (%)	Full-year Revised forecast
<Key Items of Statement of Income>							
Net sales	70,323	143,299	74,032	145,340	74,618	0.8%	148,000
Operating income	7,788	14,795	7,144	14,932	10,612	48.6%	18,000
Ordinary income	8,143	15,456	7,548	15,712	10,883	44.2%	18,400
Net income	4,149	8,297	3,995	8,709	6,681	67.2%	11,000
Net income per share (yen)	68.81	137.61	67.87	148.64	114.79	—	188.96
Net income per share (diluted) (yen)	68.70	137.42	—	—	—	—	—
<Key Items of Balance Sheet>							
Total assets	124,629	128,575	121,991	124,237	129,328	—	—
Net assets	85,216	86,027	85,663	87,243	92,169	—	—
Net assets per share (yen)	1,408.40	1,430.46	1,450.15	1,491.14	1,576.08	—	—
<Key Indicators, etc.>							
Dividend payout ratio (%)	32.0	32.0	38.3	35.0	25.3	—	30.7
Return on equity (%)	5.0	9.9	4.7	10.1	7.5	—	—
Return on asset (%)	6.6	12.3	6.0	12.4	8.6	—	—
Owners' equity ratio (%)	68.2	66.6	69.9	69.9	70.9	—	—
Number of consolidated subsidiaries	19	20	19	19	18	—	—



* Figures in the above graph are rounded to the nearest 100 million yen.

Notes:

* Each fiscal period is as follows;

FY2007 is a one-year period ending on March 31, 2008. 1H/FY2007 is a 6-month period ending on September 30, 2007.

FY2008 is a one-year period ending on March 31, 2009. 1H/FY2008 is a 6-month period ending on September 30, 2008.

FY2009 is a one-year period ending on March 31, 2010. 1H/FY2009 is a 6-month period ending on September 30, 2009.

* Figures are rounded down to the nearest million yen unless stated.

* Quarterly Report is applied from FY2008, therefore figures of 1H/FY2007 are shown as a reference.

Consolidated Balance Sheets

<ASSETS>

(Millions of yen)

	End of 1H/FY2009 (Sep 30, 2009)	End of FY2008 (Mar. 31, 2009)
<Assets>		
Current assets		
Cash and cash equivalents	18,783	14,555
Accounts and notes receivables	26,866	26,245
Marketable securities	15,500	13,000 ←①
Merchandise and finished goods	4,749	4,266
Work in process	3,901	3,655
Raw materials and supplies	3,224	3,565
Other current assets	5,278	4,436
Allowance for doubtful receivables	-50	-106
Total current assets	78,253	69,619
Fixed assets		
Property, plant and equipment		
Buildings and structures, net	12,326	12,862
Furniture and fixtures, net	6,892	7,534
Land	7,646	7,650
Other property, plant and equipment, net	2,737	2,673
Total property, plant and equipment	29,602	30,722 ←②
Intangible fixed assets		
Goodwill	3,406	3,566
Software	6,729	7,859
Other intangible fixed assets	2,029	2,081
Total intangible fixed assets	12,165	13,506 ←②
Investment and other assets		
Investment securities	2,147	2,463
Other investments and other assets	7,182	8,033
Allowance for doubtful receivables	-23	-107
Total investments and other assets	9,306	10,389
Total fixed assets	51,074	54,618
Total assets	129,328	124,237

Notes: Figures are rounded down to the nearest million yen.

- ① Marketable securities increased by 2.5 billion yen due to increase of negotiable certificate of deposit.
- ② Tangible and intangible assets decreased by 2.4 billion yen, mainly due to capital spending cuts.

Consolidated Balance Sheets

<LIABILITIES AND NET ASSETS>

(Millions of yen)

	End of 1H/FY2009 (Sep 30, 2009)	End of FY2008 (Mar. 31, 2009)
<Liabilities>		
Current liabilities		
Accounts and notes payables	9,394	9,802
Short-term loans payables	965	1,593
Accounts payable - others	4,545	4,820
Income taxes payable	4,024	2,273
Accrued bonuses	4,176	3,774
Other current liabilities	4,085	3,865
Total current liabilities	27,192	26,130
Long-term liabilities		
Long-term loans payables	153	204
Allowance for retirement benefits	5,245	6,831
Other long-term liabilities	4,566	3,828
Total long-term liabilities	9,965	10,864
Total liabilities	37,158	36,994
<Net assets>		
Owners' equity		
Capital stock	7,666	7,663
Capital surplus	23,388	23,385
Retained earnings	62,514	57,346
Treasury stock, at cost	-487	-485
Total owners' equity	93,081	87,909
Valuation and translation adjustments		
Unrealized gain on available-for-sale securities	93	25
Foreign currency translation adjustments	-1,427	-1,134
Total valuation and translation adjustments	-1,334	-1,108
Subscription rights to shares	229	192
Minority interests	192	249
Total net assets	92,169	87,243
Total liabilities and net assets	129,328	124,237

←①

Notes: Figures are rounded down to the nearest million yen.

① Income taxes payable increased by 1.7 billion yen, mainly due to increase of taxable income.

Consolidated Statement of Income

(Millions of yen)

	1H/FY2008 (Apr.1-Sep.30, 2008)	1H/FY2009 (Apr.1-Sep.30, 2009)	YoY Variance	
Net sales	74,032	74,618	585	0.8%
Cost of sales	48,386	46,181	-2,204	-4.6%
Gross profit	25,646	28,436	2,789	10.9%
Selling, general and administrative expenses	18,502	17,823	-679	-3.7%
Operating income	7,144	10,612	3,468	48.6%
Non-operating income				
Interest received	20	12		
Dividends received	75	20		
Dividends income of insurance	—	111		
Equity in net gains of associated companies	116	15		
Other non-operating income	295	174		
Total non-operating income	508	333	-174	-34.4%
Non-operating expenses				
Interest expenses	20	11		
Rent expenses	21	22		
Loss on investments in partnership	—	14		
Other non-operating expenses	62	15		
Total non-operating expenses	104	63	-40	-39.2%
Ordinary income	7,548	10,883	3,334	44.2%
Extraordinary gains				
Gain on sales of fixed assets	0	2		
Gain on sales of investment securities	108	—		
Gain on revision of retirement benefits plan	—	342		
Other extraordinary gains	36	12		
Total extraordinary gains	144	358	213	148.0%
Extraordinary loss				
Loss on disposals of fixed assets	146	74		
Loss on devaluation of investment securities	300	—		
Impairment loss	—	78		
Other extraordinary losses	25	33		
Total extraordinary loss	471	187	-284	-60.4%
Income before income taxes and minority interests	7,220	11,054	3,833	53.1%
Income taxes and enterprise taxes	2,703	4,767		
Income taxes adjustments	515	-403		
Total income taxes	3,219	4,363	1,143	35.5%
Minority interests	6	9	3	50.6%
Net income	3,995	6,681	2,686	67.2%

Notes: Figures are rounded down to the nearest million yen.

- ① Cost of sales decreased mainly due to completion of CL4800 instrument sales and decrease of depreciation resulted from capital spending cuts.
- ② Selling, general and administrative expenses decreased mainly due to decrease of depreciation resulted from capital spending cuts and reduction in general expenses.
- ③ Gain on revision of retirement benefits system of 342 million yen was posted due to the change of retirement benefit system at Fujirebio.

Segment Information (Consolidated)

<Performance by Business Segment>

(Millions of yen)

	FY2007			FY2008			FY2009		
	1H	2H	Full-year	1H	2H	Full-year	1H	YoY Variance (%)	Full-year (Revised forecast)
Net sales	70,323	72,975	143,299	74,032	71,308	145,340	74,618	0.8%	148,000
In Vitro Diagnostics	14,741	17,989	32,730	16,772	15,558	32,331	16,284	-2.9%	32,200
Clinical Lab Testing	45,440	44,768	90,208	46,090	45,018	91,108	46,566	1.0%	92,000
Others	10,141	10,218	20,359	11,169	10,731	21,901	11,767	5.3%	23,800
Clinical Trials	2,514	2,930	5,444	2,902	2,767	5,670	2,805	-3.3%	—
Sterilizing	4,984	4,985	9,970	5,675	5,794	11,469	6,081	7.2%	—
Preventive Medicine Related	2,642	2,302	4,944	2,591	2,169	4,760	2,879	11.1%	—
Operating income	7,788	7,006	14,795	7,144	7,788	14,932	10,612	48.6%	18,000
In Vitro Diagnostics	2,969	4,204	7,174	2,716	3,096	5,812	4,333	59.5%	7,150
Clinical Lab Testing	3,631	2,039	5,670	3,098	3,767	6,866	4,786	54.5%	8,650
Others	1,240	777	2,018	1,241	836	2,078	1,486	19.7%	2,100
Clinical Trials	136	307	443	236	322	558	341	44.4%	—
Sterilizing	493	319	812	467	424	891	512	9.7%	—
Preventive Medicine Related	610	150	761	537	90	627	632	17.6%	—
Elimination/corporate	-53	-14	-67	87	87	174	6	—	100

Notes: Figures are rounded down to the nearest million yen.

Segment Information (Consolidated)

(1) In Vitro Diagnostics Business

<Net Sales by Products Category>

(Billions of yen)

	FY2007			FY2008			FY2009
	1H	2H	Full-year	1H	2H	Full-year	1H
In Vitro Diagnostics	14.7	18.0	32.7	16.8	15.6	32.3	16.3
In-house products (own brand and finished products)	11.5	14.6	26.0	13.8	12.4	26.2	12.8
CL	4.9	7.5	12.5	8.9	7.4	16.2	7.7
HA·PA	3.7	3.1	6.8	2.0	1.7	3.7	1.7
EL	0.3	1.2	1.6	0.2	0.8	1.0	0.9
RI	0.6	0.6	1.1	0.6	0.5	1.1	0.5
Others	1.9	2.1	4.0	2.2	2.0	4.2	2.1
OEM, raw materials, partly-finished products, and license	3.3	3.4	6.7	2.9	3.2	6.1	3.5

Notes: Figures above are rounded to the nearest 100 million yen.

<Net Sales by Sale Destination>

(Billions of yen)

	FY2007			FY2008			FY2009
	1H	2H	Full-year	1H	2H	Full-year	1H
In Vitro Diagnostics	14.7	18.0	32.7	16.8	15.6	32.3	16.3
Overseas	3.9	3.9	7.8	4.0	3.7	7.7	4.3
Americas	2.0	1.9	3.9	2.0	2.0	3.9	2.2
Europe	1.3	1.3	2.7	1.5	1.2	2.6	1.6
Asia/Pacific	0.6	0.6	1.2	0.6	0.6	1.2	0.5
Japan	10.9	14.1	25.0	12.7	11.9	24.6	12.0

Notes: Figures above are rounded to the nearest 100 million yen.

<JPY/USD Exchange Rate during the Period>

(Yen)

	FY2007			FY2008			FY2009
	1H	2H	Full-year	1H	2H	Full-year	1H
JPY/USD	119.34	109.28	114.31	106.12	95.00	100.56	95.49

*Exchange rate for the 2nd-half of each year is calculated based on full-year exchange rate (annual average) and 1st-half exchange rate (first six-months average).

Segment Information (Consolidated)

(2) Clinical Lab Testing Business

<Net Sales by Business Category>

(Billions of yen)

	FY2007			FY2008			FY2009
	1H	2H	Full-year	1H	2H	Full-year	1H
Clinical Lab Testing	45.4	44.8	90.2	46.1	45.0	91.1	46.6
Off-site Testing	37.4	36.7	74.1	37.6	36.8	74.4	37.4
FMS/Branch Lab	8.0	8.1	16.1	8.5	8.2	16.7	9.2

Notes: Figures above are rounded to the nearest 100 million yen.

<Net Sales by Geographical Region in Japan>

(%)

		FY2007			FY2008			FY2009
		1H	2H	Full-year	1H	2H	Full-year	1H
Clinical Lab Testing		100%	100%	100%	100%	100%	100%	100%
Northern/ eastern Japan ↑ ↓ Southern/ western Japan	Hokkaido Region	5.4%	5.3%	5.3%	5.0%	5.0%	5.0%	5.1%
	Tohoku Region	6.5%	6.3%	6.4%	6.0%	6.0%	6.0%	5.9%
	Kanto Region (incl. Tokyo and metropolitan area)	36.8%	37.0%	36.9%	36.4%	36.7%	36.5%	37.4%
	Hokuriku Region	2.2%	2.3%	2.2%	2.2%	2.2%	2.2%	2.4%
	Chubu Region	10.9%	10.8%	10.8%	11.3%	11.0%	11.1%	10.5%
	Kinki Region (incl. Osaka)	12.1%	12.0%	12.0%	12.9%	12.7%	12.8%	13.2%
	Chugoku and Shikoku Region	6.7%	6.7%	6.7%	6.8%	6.8%	6.8%	6.6%
	Kyusyu Region	15.1%	14.7%	14.9%	14.8%	14.9%	14.8%	14.9%
Others (including clinical trial and outsourcing)		4.5%	4.9%	4.7%	4.5%	4.7%	4.6%	4.0%

Capital Expenditure (Consolidated)

<Research & Development Expenses>

(Millions of yen)

	FY2007			FY2008			FY2009		
	1H	2H	Full-year	1H	2H	Full-year	1H	YoY Variance (%)	Full-year (Forecast)
R&D Expenses	2,240	2,212	4,453	1,971	1,961	3,933	1,873	-5.0%	4,100
In Vitro Diagnostics	2,149	1,990	4,140	1,830	1,828	3,658	1,746	-4.6%	—
Clinical Lab Testing	91	221	312	141	132	274	127	-10.3%	—
Others	—	—	—	—	—	—	—	—	—
Miraca holdings	—	—	—	—	—	—	—	—	—

Notes: Figures are rounded down to the nearest million yen.

<Capital Expenditure>

(Millions of yen)

	FY2007			FY2008			FY2009		
	1H	2H	Full-year	1H	2H	Full-year	1H	YoY Variance (%)	Full-year (Forecast)
Capital Expenditure	5,141	7,209	12,351	3,048	2,978	6,027	2,737	-10.2%	7,000
In Vitro Diagnostics	936	1,175	2,112	967	997	1,965	887	-8.3%	—
Clinical Lab Testing	2,662	4,926	7,588	1,985	1,580	3,566	1,623	-18.3%	—
Others	75	122	198	76	336	412	223	193.9%	—
Miraca holdings	1,466	985	2,451	18	64	83	2	-87.6%	—

Notes: Figures are rounded down to the nearest million yen.

The amount of capital expenditure includes cost of leasing testing instruments/analyzers.

<Depreciation and Amortization>

(Millions of yen)

	FY2007			FY2008			FY2009		
	1H	2H	Full-year	1H	2H	Full-year	1H	YoY Variance (%)	Full-year (Forecast)
Depreciation & Amortization	4,225	4,996	9,222	5,247	5,298	10,545	4,265	-18.7%	9,000
In Vitro Diagnostics	1,168	1,300	2,468	1,247	1,272	2,519	1,100	-11.8%	—
Clinical Lab Testing	2,910	3,355	6,265	3,457	3,460	6,918	2,633	-23.8%	—
Others	141	159	300	147	165	313	163	10.9%	—
Miraca holdings	6	181	187	394	399	793	367	-6.8%	—

Notes: Figures are rounded down to the nearest million yen.

The amount of amortization and depreciation includes cost of leasing testing instruments/analyzers.

Employees (Consolidated)

<Number of Full-time Employees at End of Term>

	End of Sep.2007	Variance from the previous term	End of Mar.2008	Variance	End of Sep.2008	Variance	End of Mar.2009	Variance	End of Sep.2009	Variance
Total	4,401	-105	4,353	-48	4,484	131	4,443	-41	4,546	103
In Vitro Diagnostics	814	28	840	26	854	14	836	-18	875	39
Clinical Lab Testing	2,701	-168	2,637	-64	2,649	12	2,613	-36	2,623	10
Others	875	34	865	-10	964	99	977	13	1,032	55
Clinical Trials	135	-3	140	5	161	21	161	0	181	20
Sterilizing	637	50	610	-27	697	87	706	9	745	39
Preventive Medicine Related	103	-13	115	12	106	-9	110	4	106	-4
Miraca holdings	11	1	11	0	17	6	17	0	16	-1

Share of Stock

<Stock Information >

	End of Sep.2007	End of Mar.2008	End of Sep.2008	End of Mar.2009	End of Sep.2009
Number of shares issued (thousands of share)	60,868	61,040	61,040	58,440	58,442
Number of shareholders	7,824	7,234	7,043	6,888	7,606
Share price (yen)	2,605	2,605	2,040	1,988	2,930
Aggregate market value of listed stock (billions of yen)	157.2	156.0	120.0	115.7	170.6

Notes: The number of issued shares includes treasury stocks.

Aggregated market value of listed stock is calculated on the basis of the number of shares excluding treasury stocks. (Figures of aggregated market value of listed stock is rounded to the nearest 100 million yen)

<Treasury Stock>

	End of Sep.2007	End of Mar.2008	End of Sep.2008	End of Mar.2009	End of Sep.2009
Number of treasury stocks	541,378	1,145,117	2,226,120	228,529	229,300

<Shareholder Distribution>

	End of Sep.2007	End of Mar.2008	End of Sep.2008	End of Mar.2009	End of Sep.2009
Financial institutions in Japan	37.39%	36.53%	31.99%	34.35%	40.64%
Overseas investors	42.89%	43.94%	47.21%	47.98%	41.93%
Individuals and others in Japan	16.49%	15.38%	14.73%	15.08%	14.80%
Companies in Japan	1.90%	1.87%	1.86%	1.95%	1.93%
Securities companies in Japan	0.44%	0.40%	0.56%	0.25%	0.30%
Treasury stocks	0.89%	1.88%	3.65%	0.39%	0.40%

<Cash Dividends per Share>

	FY2007	FY2008
Interim dividends	22	26
Year-end dividends	22	26
Annual dividends per share	44	52

(yen/share)

FY2009	
	29
(Forecast)	29
(Forecast)	58